 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Arizona. The poster, titled An Open-Label Tolerability and Efficacy Study of ZYN002 cannabidiol Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome INSPIRE, shows that through 38 weeks of treatment, statistically significant improvements were seen in children and adolescents treated with Zygel in the Pediatric Anxiety Rating Scale PARS-R, all five scales of the Anxiety, Depression and Mood Scale ADAMS, and all five subscales of the Aberrant Behavior Checklist Community ABC-C. 